| Trial ID: | L2349 |
| Source ID: | NCT00184626
|
| Associated Drug: |
Biphasic Insulin Aspart
|
| Title: |
Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart|DRUG: insulin glargine|DRUG: metformin
|
| Outcome Measures: |
Primary: HbA1c, Measured at end of treatment (26 weeks) | Secondary: safety variables|other glycemic variables|Fasting plasma glucose value
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
97
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-09-10
|
| Completion Date: |
2005-10-24
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-24
|
| Locations: |
Novo Nordisk Investigational Site, Istanbul, 111, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT00184626
|
